|
ALDX Aldeyra Therapeutics Inc 1341235 |
| Income Statement |
|
Net Income
|
2026-06-30
|
$-5,450,273.00 |
| Balance Sheet |
|
Current Assets
|
$47,378,906.00 |
|
Assets
|
$47,540,559.00 |
|
Current Liabilities
|
$9,655,256.00 |
|
Liabilities
|
$9,655,256.00 |
|
Equity
|
$37,885,303.00 |
|
Shares Out
|
60321068.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-9,699,511.00 |
|
Investing Cash Flow
|
$-23,097.00 |
| Market Analysis |
Market Cap
|
$90,481,602.00 |
|
Price
|
$1.50 |
|
BVPS
|
0.63 |
|
PB
|
2.38 |
|
EPS
|
-0.09 |
|
FCF
|
$-9,699,511.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-09-01 09:32:50 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-09-14 10:01:41 |
|
| Jan |
Feb |
Mar |
|
|
|
|
2026-02-27 |
-0.56 |
|
| Apr |
May |
Jun |
|
|
|
|
2026-05-07 |
-0.06 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-07 |
-0.16 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-05 |
-0.13 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view ALDX documents filed with the SEC.
ALDX Filings
Clear
